Trial
NCT02443337
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
SCRI Development Innovations, LLC
Condition
Non-small Cell Lung Cancer Metastatic
Intervention
LY3023414
Why stopped
The study stopped due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-09